Literature DB >> 2720530

Cyclosporine-induced deterioration in patients with AIDS.

A Phillips1, M A Wainberg, R Coates, M Klein, A Rachlis, S Read, F Shepherd, H Vellend, S Walmsley, P Halloran.   

Abstract

Eight patients with AIDS (acquired immune deficiency syndrome) but free of life-threatening infection were treated with the immunosuppressive drug cyclosporine for a mean of 53.9 days. The serum cyclosporine levels were maintained in the desired therapeutic range. All eight patients experienced severe toxic symptoms, which necessitated discontinuation of cyclosporine therapy in six. The serum levels of creatinine, urea and potassium rose during treatment and fell after therapy was stopped. The total leukocyte count, hemoglobin level, platelet count, total T-cell count, and T4- and T8-cell counts all fell markedly during treatment. The total leukocyte count, platelet count, and T4- and T8-cell counts rose after therapy was stopped, but the hemoglobin level remained low. No patient experienced resolution of symptoms during therapy, and the condition of all patients improved after treatment was stopped. The results of this pilot study indicate that cyclosporine does not alleviate, and may worsen, the symptoms and laboratory findings in patients with AIDS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720530      PMCID: PMC1269983     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  19 in total

1.  The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1.

Authors:  M A Wainberg; A Dascal; N Blain; L Fitz-Gibbon; F Boulerice; K Numazaki; M Tremblay
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

2.  AIDS. Politics of premature French claim of cure.

Authors:  R Walgate
Journal:  Nature       Date:  1985 Nov 7-13       Impact factor: 49.962

3.  Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma.

Authors:  S E Krown; F X Real; S Cunningham-Rundles; P L Myskowski; B Koziner; S Fein; A Mittelman; H F Oettgen; B Safai
Journal:  N Engl J Med       Date:  1983-05-05       Impact factor: 91.245

4.  Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo.

Authors:  S Broder; R Yarchoan; J M Collins; H C Lane; P D Markham; R W Klecker; R R Redfield; H Mitsuya; D F Hoth; E Gelmann
Journal:  Lancet       Date:  1985-09-21       Impact factor: 79.321

5.  Elevated levels of interferon-induced 2'-5' oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome.

Authors:  S E Read; B R Williams; R A Coates; W K Evans; M M Fanning; M B Garvey; F A Shepherd
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

6.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

Authors:  C R Stiller; J Dupré; M Gent; M R Jenner; P A Keown; A Laupacis; R Martell; N W Rodger; B von Graffenried; B M Wolfe
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

7.  Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes.

Authors:  J B McCormick; J P Getchell; S W Mitchell; D R Hicks
Journal:  Lancet       Date:  1984-12-15       Impact factor: 79.321

8.  An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells.

Authors:  R B Stricker; T M McHugh; D J Moody; W J Morrow; D P Stites; M A Shuman; J A Levy
Journal:  Nature       Date:  1987 Jun 25-Jul 1       Impact factor: 49.962

Review 9.  Prospects of therapy for infections with human T-lymphotropic virus type III.

Authors:  M S Hirsch; J C Kaplan
Journal:  Ann Intern Med       Date:  1985-11       Impact factor: 25.391

10.  Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

View more
  17 in total

Review 1.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506.

Authors:  A Karpas; M Lowdell; S K Jacobson; F Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

Review 3.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

4.  AIDS trials, civil liberties and the social control of therapy: should we embrace new drugs with open arms?

Authors:  D A Salisbury; M T Schechter
Journal:  CMAJ       Date:  1990-05-15       Impact factor: 8.262

Review 5.  Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

Authors:  S D Lawn; S T Butera; T M Folks
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.

Authors:  G Paolo Rizzardi; Alexandre Harari; Brunella Capiluppi; Giuseppe Tambussi; Kim Ellefsen; Donatella Ciuffreda; Patrick Champagne; Pierre-Alexandre Bart; Jean-Philippe Chave; Adriano Lazzarin; Giuseppe Pantaleo
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

7.  Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.

Authors:  K D Bell; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

8.  Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Authors:  Roger G Ptak; Philippe A Gallay; Dirk Jochmans; Andrew P Halestrap; Urs T Ruegg; Luke A Pallansch; Michael D Bobardt; Marie-Pierre de Béthune; Johan Neyts; Erik De Clercq; Jean-Maurice Dumont; Pietro Scalfaro; Kamel Besseghir; Roland M Wenger; Brigitte Rosenwirth
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

Review 9.  Understanding the benign nature of SIV infection in natural hosts.

Authors:  Guido Silvestri; Mirko Paiardini; Ivona Pandrea; Michael M Lederman; Donald L Sodora
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

Review 10.  Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors.

Authors:  A Roulston; R Lin; P Beauparlant; M A Wainberg; J Hiscott
Journal:  Microbiol Rev       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.